<DOC>
	<DOC>NCT01068951</DOC>
	<brief_summary>The main hypothesis of the investigators study is that the development of autoimmune diabetes may be halted att diagnosis by the immune modulatory properties of mesenchymal stem cells.</brief_summary>
	<brief_title>Treatment of Patients With Newly Onset of Type 1 Diabetes With Mesenchymal Stem Cells</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<criteria>Ability to provide written informed consent Mentally stable and able to comply with the procedures of the study protocol Clinical history compatible with type 1 diabetes diagnosed less than 10 days of enrolment Stimulate cpeptide &gt;0.1 nmol/l Patients with BMI&gt;30 Patients with unstable cardiovascular status Patients with active infections, unless treatment is not judged necessary by the investigators Patients with serological evidence of infection with HIV, hepatitis B or hepatitis C. Sexually active females who are not a) postmenopausal, b) surgically sterile or c) using an acceptable method of contraception: oral contraceptives, Norplant, Depoprovera and barrier devices combined with spermicidal gel are acceptable. Patients with known or previous malignancy. Patient with any condition or any circumstance that in the opinion of the investigator would make it unsafe to undergo treatment with autologous MSC.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>type 1 diabetes</keyword>
	<keyword>mesenchymal stem cells</keyword>
	<keyword>intervention</keyword>
</DOC>